Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
Rhea-AI Summary
Satellos (NASDAQ: MSLE) reported Q1 2026 results and clinical progress for SAT-3247 in Duchenne muscular dystrophy. Cash and equivalents were $69.9M (Cdn $97.5M), with runway through 2027.
Phase 2 BASECAMP is enrolling across 11 sites, targeting Q3 2026 enrollment completion, while adult Phase 2 TRAILHEAD has been initiated in the U.S. Net loss was $9.8M ($0.53/share), driven by higher R&D and G&A expenses tied to clinical activities and the Nasdaq uplisting.
Positive
- Cash, cash equivalents and short-term investments of $69.9M with runway through 2027
- $57M equity raise completed in February 2026
- Phase 2 BASECAMP trial enrolling at 11 clinical centers, with more sites planned in Q2 2026
- Phase 2 TRAILHEAD adult DMD study initiated in the U.S.
- Four prior Phase 1b participants re-enrolled into TRAILHEAD for long-term SAT-3247 treatment
- R&D investment increased to $7.3M, supporting SAT-3247 BASECAMP and TRAILHEAD studies
Negative
- Q1 2026 net loss increased to $9.8M from $6.1M a year earlier
- Loss per share widened to $0.53 from $0.44 in Q1 2025
- R&D expenses rose to $7.3M from $4.5M year over year
- G&A expenses increased to $2.7M from $1.9M, reflecting higher headcount and listing costs
News Market Reaction – MSLE
In the May 15 session, MSLE declined 2.23%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 27 | Earnings results | Positive | -10.7% | Reported 2025 results, Nasdaq listing, $57.2M equity financing, and Phase 2 trial starts. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
The last earnings-related announcement on Mar 27, 2026 coincided with a -10.68% 24-hour move, indicating past earnings updates have drawn a negative price reaction.
Over recent months, Satellos has focused on advancing SAT-3247 and strengthening its listing profile. On Feb 18 and Feb 24, it highlighted upcoming and hosted events detailing Phase 1a/b data and the Phase 2 BASECAMP and TRAILHEAD studies. A Mar 10 data update showed functional and biomarker signals, followed by 2025 results on Mar 27 that included a $57.2M financing and Nasdaq listing. Today’s Q1 2026 results extend that narrative with higher R&D spend and cash of $69.9M, supporting runway through 2027.
Key Terms
phase 2 medical
open-label medical
duchenne muscular dystrophy medical
equity offering financial
short-term investments financial
biomarker medical
net loss financial
research and development financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026
- BASECAMP remains on track to complete enrollment in Q3 2026
- The Company has initiated the TRAILHEAD study in the U.S. in adults aged 16-25 years.
- Current cash available of
$69.9M (Cdn$97.5M ) provides runway through 2027
TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced financial results and corporate highlights for the first quarter ended March 31, 2026.
“The first quarter of 2026 was a productive time for Satellos. We raised
SAT-3247 CLINICAL PROGRESS
SAT-3247 is an orally administered small-molecule therapy designed to enhance muscle regeneration by addressing deficits in muscle stem cell polarity in Duchenne and potentially other muscle diseases.
BASECAMP (CL-201): Phase 2 Pediatric Study
The BASECAMP study is evaluating SAT-3247 in 51 ambulatory boys with DMD aged 7, 8 or 9 years. Primary endpoints include safety, tolerability and dynamometry. Secondary endpoints will assess SAT-3247’s impact on muscle quality, function and regeneration.
The BASECAMP trial is actively enrolling at 11 clinical centers. The Company anticipates activating additional clinical sites throughout Q2 2026.
TRAILHEAD (LT-001): Phase 2 Adult Study
TRAILHEAD is a 12-month, open-label Phase 2 study evaluating long-term safety, efficacy and sustained functional benefit of SAT-3247 in adults with DMD.
- After submitting TRAILHEAD to the FDA in early Q2 2026 and following the statutory review period, Satellos began to engage with its planned clinical sites in the U.S. to identify participants with DMD aged 16 to 25 years.
- Four participants from the Company’s Phase 1b study (CL-101) enrolled in TRAILHEAD and restarted on SAT-3247 at various times in Q4 2025; they are expected to complete six months on drug at various times during Q2 2026
- Satellos plans to enroll up to 30 individuals living with DMD aged ≥16 to 25 years in the U.S. and Australia
- The Company intends to provide updates from the TRAILHEAD study throughout 2026
FINANCIAL RESULTS
Satellos had cash and cash equivalents and short-term investments of
For the quarter ended March 31, 2026, Satellos reported a net loss of
R&D expenses increased to
G&A expenses increased to
Satellos’ financial statements for the quarter ended March. 31, 2026, and the related management’s discussion and analysis (MD&A) will be available on the Company website and SEDAR+ at www.sedarplus.ca.
ABOUT SAT-3247
SAT-3247 is a proprietary, oral, small molecule drug candidate being developed by Satellos as a novel approach to regenerating skeletal muscle lost in Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases or injury conditions. Satellos is advancing SAT-3247 as a potential treatment for DMD that is independent of dystrophin and applicable regardless of exon mutation status, with ongoing Phase 2 clinical studies, including TRAILHEAD, an open-label study in adult participants, and BASECAMP, a global, randomized, placebo-controlled study in pediatric participants.
ABOUT SATELLOS BIOSCIENCE INC.
Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, Satellos has developed SAT-3247, a first-of-its-kind, orally administered small molecule therapy designed to address deficits in muscle repair and regeneration. SAT-3247 is being evaluated as a potential disease-modifying treatment, initially for DMD, in two Phase II clinical trials: BASECAMP in pediatrics and TRAILHEAD in adults. SAT-3247 targets AAK1, a key protein that Satellos has identified as capable of helping restore the body’s natural muscle repair and regeneration biology, a fundamental stem cell driven process that is disrupted in DMD and other degenerative conditions. By inhibiting AAK-1, SAT-3247 treatment aims to re-establish a biochemical signal needed to support muscle regeneration in a dystrophin-independent manner — with potential broad applicability as either a stand-alone or adjunctive therapy. Satellos has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development. For more information, visit www.satellos.com.
NOTICE ON FORWARD-LOOKING STATEMENTS
This press release includes forward-looking information or forward-looking statements within the meaning of applicable securities laws regarding Satellos and its business, which may include, but are not limited to, statements regarding expected runway; the possibility of pursuing regulatory approval for SAT-3247; the potential for SAT-3247 to represent a disease modifying approach to the therapeutic treatment of people living with Duchenne; anticipated benefits to patients from a small molecule treatment for Duchenne; the advancement SAT-3247 through clinical trials, including the BASECAMP clinical trial and the expected timing of enrollment and top-line data; the activation of additional clinical sites; expected participants in the TRAILHEAD study; the pharmacodynamic properties and mechanism-of-action of SAT-3247; the potential of our approach in other degenerative muscle diseases and our plans to pursue those opportunities; SAT-3247’s prospective impact on Duchenne patients, patients with other degenerative muscle disease or muscle injury or trauma, and on muscle regeneration generally; and Satellos’ technologies and drug development plans. All statements that are, or information which is, not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, occurrences or developments, are “forward-looking information or statements.” Often, but not always, forward-looking information or statements can be identified by the use of words such as “shall”, “intends”, “believe”, “plan”, “expect”, “intend”, “estimate”, “anticipate”, “potential”, “prospective” , “assert” or any variations (including negative or plural variations) of such words and phrases, or state that certain actions, events or results “may”, “might”, “can”, “could”, “would” or “will” be taken, occur, lead to, result in, or, be achieved. Such statements are based on the current expectations and views of future events of the management of the Company. These statements are based on assumptions and subject to risks and uncertainties. Although management believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release, may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including, without limitation, risks relating to the pharmaceutical and bioscience industry (including the risks associated with preclinical and clinical trials and regulatory approvals), the research and development of therapeutics, the results of preclinical and clinical trials, general market conditions and equity markets, economic factors and management’s ability to manage and to operate the business of the Company generally, including inflation and the costs of operating a biopharma business, and those risks and uncertainties described in more detail in the “Risk Factors” section of Satellos’ Annual Information Form dated March 26, 2025 (which is located on Satellos’ profile at www.sedarplus.ca) and in Satellos’ public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Satellos has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Satellos does not undertake any obligation to publicly update or revise any forward-looking statement, whether resulting from new information, future events, or otherwise
CONTACTS
Investors: Dan Ferry, LifeSci Advisors, daniel@lifesciadvisors.com
Media: Emily Williams, Senior Director of Communications, media@satellos.com
